atenolol has been researched along with Breast Cancer in 6 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin can induce breast cancer (BC) cell apoptosis and reduce BC local and metastatic growth in preclinical models." | 7.83 | Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. ( Albini, A; Bertolini, F; Calleri, A; Dallaglio, K; Gregato, G; Labanca, V; Mancuso, P; Noonan, DM; Orecchioni, S; Reggiani, F; Rossi, T; Talarico, G, 2016) |
| " Association between the use of reserpine and breast cancer in women, between atenolol and some types of cancer in elderly men also can not be ruled out." | 4.81 | [Antihypertensive drugs and malignant neoplasia]. ( Kiktev, VG; Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM, 2002) |
| "Metformin can induce breast cancer (BC) cell apoptosis and reduce BC local and metastatic growth in preclinical models." | 3.83 | Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. ( Albini, A; Bertolini, F; Calleri, A; Dallaglio, K; Gregato, G; Labanca, V; Mancuso, P; Noonan, DM; Orecchioni, S; Reggiani, F; Rossi, T; Talarico, G, 2016) |
| "The association between diuretics and renal cell carcinoma was analysed in 4389 cases and 6566 controls, yielding a pooled OR of 1." | 2.41 | Antihypertensive therapy and the risk of malignancies. ( Goldbourt, U; Grossman, E; Messerli, FH, 2001) |
| "Propranolol users were significantly less likely to present with a T4 (odds ratio [OR], 0." | 1.37 | Beta blockers and breast cancer mortality: a population- based study. ( Barron, TI; Bennett, K; Connolly, RM; Sharp, L; Visvanathan, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Talarico, G | 1 |
| Orecchioni, S | 1 |
| Dallaglio, K | 1 |
| Reggiani, F | 1 |
| Mancuso, P | 1 |
| Calleri, A | 1 |
| Gregato, G | 1 |
| Labanca, V | 1 |
| Rossi, T | 1 |
| Noonan, DM | 1 |
| Albini, A | 1 |
| Bertolini, F | 1 |
| Friedman, GD | 1 |
| Udaltsova, N | 1 |
| Habel, LA | 1 |
| Ganz, PA | 1 |
| Cole, SW | 1 |
| Barron, TI | 1 |
| Connolly, RM | 1 |
| Sharp, L | 1 |
| Bennett, K | 1 |
| Visvanathan, K | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Sidorenko, BA | 1 |
| Stetsenko, TM | 1 |
| Kiktev, VG | 1 |
| Grossman, E | 1 |
| Messerli, FH | 1 |
| Goldbourt, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Melablock: A Multicentre Randomized, Double---blinded and Placebo---controlled Clinical Trial on the Efficacy and Safety of Once Daily Propranolol 80 mg Retard for the Prevention of Cutaneous Malignant Melanoma Recurrence[NCT02962947] | Phase 2/Phase 3 | 546 participants (Anticipated) | Interventional | 2017-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for atenolol and Breast Cancer
| Article | Year |
|---|---|
[Antihypertensive drugs and malignant neoplasia].
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Age Factors; Aged; Angiotensin-Converting | 2002 |
Antihypertensive therapy and the risk of malignancies.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2001 |
4 other studies available for atenolol and Breast Cancer
| Article | Year |
|---|---|
Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells.
Topics: Adipose Tissue, White; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Asp | 2016 |
Norepinephrine antagonists and cancer risk.
Topics: Atenolol; Breast Neoplasms; Clonidine; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Male; Meto | 2011 |
Expanding our therapeutic options: Beta blockers for breast cancer?
Topics: Adrenergic beta-Antagonists; Atenolol; Breast Neoplasms; Diabetes Complications; Disease-Free Surviv | 2011 |
Beta blockers and breast cancer mortality: a population- based study.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Breast Neoplasms; Disease Progression; Female; Humans; | 2011 |